Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmblemHealth Formulary Coverage & Prior Auth | Ope…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentEmblemHealthPolicy N/A

    2026 Formulary (List of Covered Drugs)

    Customize your policy alerts

    Sign up for all EmblemHealth policy alerts

    Know when EmblemHealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document lists covered drugs, tiers, and formulary rules (prior authorization, step therapy, quantity limits, specialty, limited distribution) for EmblemHealth members; it is intended for members and providers using EmblemHealth plans.

    Policy Summary
    PayerEmblemHealth
    Policy2026 Formulary (List of Covered Drugs)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateMar 1, 2026
    Last ReviewMar 1, 2026
    Next Review DateN/A
    Key ActionSubmit a prior authorization request when a product lists PA in the Requirements/Limits field to obtain coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Mar 1, 2026formulary effective/updated date
    877-793-6253member services phone
    PA/QL/ST/SPcoverage controls present
    XCHGformulary identifier
    20+drug classes listed

    Coverage rules and management indicators

    General formulary coverage logic

    Covered when the Member’s benefit plan allows the drug and any listed formulary controls are met:

    Formulary coverage controls: Drugs listed may be subject to one or more plan controls (PA, QL, SP, LD, ST). Coverage is determined by the drug's formulary tier and is contingent on meeting the listed requirements and the member's Certificate of Coverage.

    See plan Certificate of Coverage and formulary abbreviations for definitions and applicability.

    Coverage management indicators

    Coverage and management status is indicated on each formulary line by Drug Tier and Requirements/Limits codes:

    Formulary entries with management codes: Each drug entry includes a Drug Tier and one or more Requirement/Limit codes (examples: AC, PA, QL, LD, SP, ST). Coverage and any member cost-sharing depend on the tier and fulfillment of the listed codes.

    This document segment provides operational flags only; consult per-drug listing for exact codes and quantities.

    Policy Summary
    PayerEmblemHealth
    Policy2026 Formulary (List of Covered Drugs)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateMar 1, 2026
    Last ReviewMar 1, 2026
    Next Review DateN/A
    Key ActionSubmit a prior authorization request when a product lists PA in the Requirements/Limits field to obtain coverage.
    SourceLink
    On This Page
    Coverage rules and management indicatorsFormulary drug listings, tiers, and quantity examplesPrior authorization, step therapy, documentation, and denial risksStep therapy markers and affected productsPer-product quantity limits and examplesSpecialty, limited distribution, and channel routingAbbreviations and Requirement/Limit code meaningsFormulary grouping and scopeBiosimilar listings and associated requirements
    Common Requirement/Limit codes: AC = administrative/ACA-related code; PA = Prior Authorization required; QL = Quantity Limit (specific amount/period listed); LD = Limited Distribution; SP = Specialty pharmacy routing; ST = Step Therapy.

    Definitions and implications for each code are in the formulary abbreviations.

    Formulary utilization controls

    Per-drug utilization controls (examples shown on each formulary line):

    Per-drug requirements: Each listed drug line contains: Drug Tier; Requirements/Limits (one or more of PA, QL with specified quantity and period, LD, SP, ST). Adjudication requires applying those listed controls for the specific formulation/strength.

    Use the Requirements/Limits for the exact QL values and adjudication windows (e.g., QL (30 tablets/30 days), QL (84 tablets/28 days)).

    Examples of utilization controls: Examples in this segment include: PA + QL (e.g., abiraterone PA, QL 120/30d), LD + PA + QL + SP for many oncology agents (e.g., alectinib, brigatinib), and QL-only entries with explicit quantities and intervals for antiviral and other agents (e.g., ledipasvir/sofosbuvir QL 28/28d, MAVYRET QL 84/28d).

    Refer to each product line for the exact control set for that formulation.

    Please consult the member's Certificate of Coverage for plan-specific details. Not all drugs listed in this formulary are covered by every drug benefit plan; coverage depends on the member's specific benefits, copays, and any plan-level requirements. If you have questions about a member's drug benefits, contact the phone number on the back of the member ID card as directed in the formulary materials.

    The extract contains no clinical exclusions in the presented segments. EmblemHealth affirms nondiscrimination and accessibility obligations and provides resources for reasonable modifications, language assistance, and grievance submission; providers or members needing these services should contact Customer Service or the Civil Rights Coordinator per the contact instructions in the formulary.

    This portion of the document does not set out explicit clinical coverage criteria, medical necessity determinations, or "not medically necessary" statements. Instead, the content lists formulary product lines with assigned Drug Tiers and operational controls (e.g., PA, QL, LD, SP, AC) that govern coverage and claims adjudication.

    No exclusionary clinical conditions are provided in this segment. The entries focus on product listings and the associated utilization management and administrative flags rather than on explicit exclusion criteria for clinical indications.

    There are no clinical exclusion rules listed in this portion of the formulary extract. The text emphasizes formulary controls such as Prior Authorization (PA), Quantity Limits (QL), Limited Distribution (LD), and Specialty (SP) routing that affect coverage and dispensing.

    This segment does not provide specific clinical exclusions. Coverage entries are presented as product lines with tier and requirement/limit annotations (for example, PA and QL) rather than as statements excluding particular diagnoses or patient groups.

    No formal medical necessity criteria are described in these chunks. The listed content comprises formulary listings and associated operational controls (e.g., PA, QL, LD, SP) which indicate how coverage will be managed at claim adjudication, but the extract does not include the underlying clinical criteria used to approve or deny prior authorizations.

    This portion of the document does not state medical necessity criteria or exclusionary language. Instead, product entries are shown with their formulary tier and requirement/limit flags (for example, quantity limits such as QL (120 tablets/30 days)) that define dispensing constraints to be applied during claims processing.

    There are no explicit 'not medically necessary' (NMN) determinations in the provided extract. The formulary lines shown are operational listings with requirements/limits and administrative flags rather than NMN rulings.

    This extract does not specify any NMN determinations. Coverage control in these chunks is expressed via utilization management markers (PA, QL, LD, SP) and not through 'not medically necessary' statements.

    No specific not‑medically‑necessary conditions are listed in this segment. The content lists drugs, tiers, and requirements but does not provide explicit NMN rulings or clinical exclusion criteria.

    Formulary drug listings, tiers, and quantity examples

    Aminoglycosides & Inhaled Antibiotics (selected)mixed
    ARIKAYCEamikacin sulfate liposome inhalation suspension 590 mg/8.4 mL — Requirements/Limits: LD, PA, QL (28 vials/28 days), SP, Drug Tier = 3
    TOBItobramycin nebulization solution 300 mg/5 mL — Requirements/Limits: SP, Drug Tier = 1/3 depending on formulation
    KITABIS PAKtobramycin nebulization solution kit 300 mg/5 mL — Requirements/Limits: LD, SP, Drug Tier = 3
    TOBI PODHALERtobramycin inhalation capsules 28 mg — Requirements/Limits: LD, SP, QL where applicable, Drug Tier = 3
    Tobramycin Nebu Soln (Bethkis)tobramycin nebulization solution 300 mg/4 mL (Bethkis) — Requirements/Limits: SP, Drug Tier = 1
    Neomycinneomycin sulfate tab 500 mg — Requirements/Limits: Drug Tier = 1
    Antivirals & HIV Agents (selected)mixed
    abacavirabacavir sulfate solution 20 mg/mL; tabs 300 mg — QL (960 mL/30 days for solution); QL (60 tablets/30 days)
    acycloviracyclovir cap/tab/suspensions (200 mg cap; susp 200 mg/5 mL; tabs 400 mg, 800 mg) — Drug Tier = 1
    APRETUDEcabotegravir IM extended-release suspension 600 mg/3 mL — Requirements/Limits: AC, LD, SP, Drug Tier = 2
    Protease inhibitorsexamples include darunavir (Prezista) tabs 600/800 mg — QL; atazanavir (Reyataz) caps 150/200/300 mg — QL; lopinavir-ritonavir (Kaletra) soln & tabs — QL
    Integrase inhibitorsexamples include raltegravir (ISENTRESS) chew/tab/packet — QL (various 60–180 counts); bictegravir (Biktarvy) combos with QL (30 tablets/30 days)
    Combination regimensNumerous combination regimens listed (e.g., BIKTARVY, DOVATO, GENVOYA, STRIBILD, DELSTRIGO, DESCOVY, TRUVADA) — many with QL (typically 30 tablets/30 days) and AC/QL as noted
    HCV Regimens (selected)mixed
    EPCLUSAsofosbuvir-velpatasvir (tablets & pellet packs) — Requirements/Limits: PA, QL (28 tablets/28 days or 28 packets/28 days), SP, Drug Tier = 1/2 depending on form
    HARVONIledipasvir-sofosbuvir (tabs & pellet packs) — Requirements/Limits: PA, QL (28 tablets/28 days or packets), SP
    MAVYRETglecaprevir-pibrentasvir (tabs & pellet packs) — Requirements/Limits: PA, QL (84 tablets/28 days for tablets; 140 packets/28 days for pellets), SP
    LEDIPASVIR/SOFOSBUVIRledipasvir-sofosbuvir (see HARVONI) — PA, QL (28 tablets/28 days), SP
    SOFOSBUVIR/VELPATASVIRsofosbuvir-velpatasvir (SOFOSBUVIR/VELPATASVIR) — PA, QL (28 tablets/28 days), SP
    VOSEVIsofosbuvir-velpatasvir-voxilaprevir — PA, QL (28 tablets/28 days), SP
    SOVALDIsofosbuvir (tabs & pellet packs) — PA, QL (28 tablets/28 days or packets), SP
    Additional Quantity Limit Examples (selected)mixed
    ItraconazoleQL examples: 120 capsules/30 days (capsules); oral solution QL 1200 mL/30 days
    ISENTRESS / ISENTRESS HDISENTRESS QL examples: 60 packets/30 days (packet), 60 tablets/30 days (400 mg), ISENTRESS HD QL 60 tablets/30 days
    HCV QLsMAVYRET QL 84 tablets/28 days; EPCLUSA/HARVONI/LEDIPASVIR-SOFOSBUVIR QL 28 tablets/28 days (or packets)
    Coverage Notes & Constraintsmixed
    PA NotesMany high-cost antiviral and HCV regimens require Prior Authorization (PA) and are subject to Special Program (SP) and/or Limited Distribution (LD) as indicated
    QL NotesQuantity limits (QL) frequently apply to HIV/HCV agents and inhaled antibiotics — see product-specific QLs (examples consolidated above)
    Preservation of Existing Entriesmixed
    Full formularyAll other formulary listings, tiers, and requirements previously present in this section remain unchanged and preserved (penicillins, cephalosporins, macrolides, tetracyclines, antifungals, antidiabetics, insulins, antineoplastics, vaccines, contraceptives, etc.)
    Instructional / Implementationmixed
    Provider guidanceWhen processing claims, apply the specific PA, LD, SP, and QL flags for the named products above. Use formulary tiering as listed for benefit determinations.

    Prior authorization, step therapy, documentation, and denial risks

    Prior Authorization

    Prior Authorization, Step Therapy, documentation, and denial risks

    Prior Authorization (PA), Step Therapy (ST), Limited Distribution (LD), Quantity Limits (QL), and Specialty (SP) routing are actively used across this formulary to manage access and coverage. Many high-cost, specialty, antiviral, antifungal, hepatitis, antineoplastic, endocrine, biologic, and other specialty-labeled drugs require prior authorization or are subject to step therapy, limited distribution, quantity limits, or specialty pharmacy routing. Failure to obtain required PA, to follow step therapy where specified, or to adhere to LD/SP routing and QL restrictions may result in denial of coverage.

    • PA = Prior Authorization required before the plan will cover the drug; lack of PA can result in non-coverage.
    • ST = Step Therapy: member must trial specified preferred agents first; exceptions may be requested.
    • LD = Limited Distribution: drug may only be available from select pharmacies or supply channels.
    • QL = Quantity Limit: maximum units supplied in a specified time period (e.g., 28 tablets/28 days).
    • SP = Specialty product — may require specialty pharmacy, special handling, monitoring, or education.
    Prior Authorization

    Prior authorization required for selected agents

    Selected high-cost antiviral, antifungal, hepatitis B/C, and other specialty agents listed in the formulary explicitly show PA in the Requirements/Limits field. Examples include ledipasvir/sofosbuvir, sofosbuvir-containing products (SOVALDI), sofosbuvir/velpatasvir, MAVYRET (glecaprevir-pibrentasvir), CRESEMBA (isavuconazonium), posaconazole formulations, and many antivirals listed with 'PA'. These products commonly also carry SP and QL flags.

    • Hepatitis C agents (e.g., LEDIPASVIR/SOFOSBUVIR, SOFOSBUVIR/VELPATASVIR, SOVALDI, MAVYRET) = PA, QL, SP.
    • Selected antifungals (e.g., CRESEMBA, posaconazole) = PA (and may have QL).
    • Many antivirals and HBV/HCV agents list PA next to the product — confirm PA prior to dispensing.
    Prior Authorization

    Prior authorization and distribution requirements

    Numerous specialty products require both PA and limited distribution or specialty routing (LD/SP). Examples include oncology agents, complex biologics, enzyme replacements, cystic fibrosis modulators, and infusions that are designated LD and SP; these programs often restrict where the drug can be dispensed and require PA documentation.

    • Oncology agents (many entries) = LD + PA + QL + SP in Requirements/Limits.
    • Cystic fibrosis modulators and enzyme therapies (e.g., KALYDECO, ORKAMBI, STRENSIQ) = LD + PA + QL + SP.
    • Specialty injectables and infusions (e.g., ACTHAR, ENTYVIO PEN, BYLVAY examples in formulary) require PA and may be limited to specialty channels.
    Prior Authorization

    Prior authorization and limits required

    Prior authorization is commonly paired with quantity limits and other program flags; several specialty and antineoplastic products list PA plus QL and SP (and often LD). Examples: abiraterone (Zytiga), alectinib (ALECENSA), brigatinib (ALUNBRIG), and many other antineoplastics. When PA is required, the specific Quantity Limit (e.g., 60 tablets/30 days) is listed in the Requirements/Limits field and must be respected.

    • Antineoplastics: many require LD + PA + QL + SP.
    • PA + QL examples: NEXLETOL and NEXLIZET = PA, QL (30 tablets/30 days).
    • Dose pack or packet limits are enforced (e.g., MAVYRET pellet pack QL 140 packets/28 days).
    Prior Authorization

    Prior authorization requirement

    Many formulary segments explicitly show 'PA' in the Requirements/Limits field for drugs across therapeutic classes — oncology, biologics, specialty endocrine agents, pulmonary antifibrotics, cystic fibrosis therapies, and numerous injectables. Confirm PA prior to dispensing to avoid claim denials.

    • Specialty endocrine and metabolic agents (e.g., ACTHAR, SKYTROFA) frequently show LD, PA, SP.
    • Pulmonary antifibrotics (e.g., OFEV) and CF modulators (e.g., KALYDECO, ORKAMBI) = LD, PA, QL, SP.
    • Biologic agents and many injectables list PA in Requirements/Limits — verify PA status during prior authorization submission.
    Denial Risk

    Utilization management triggers and denial risk

    PA, QL, LD, and SP flags are utilization management triggers. Products with these flags can be denied if the documented clinical criteria, PA forms, or distribution channel requirements are not satisfied. Providers should submit clinical justification and supporting documentation matching the Requirement/Limit codes.

    • PA/ST/SP may trigger denial when prior steps or documentation are not supplied.
    • QL exceedance can result in partial or full denial; documentation must support dose and quantity requested.
    • LD and SP items require dispensing through authorized channels — dispensing outside those channels may lead to denial or recoupment.
    Documentation Required

    Documentation for PA, LD, QL, and specialty drugs

    Documentation expectations: when a formulary entry lists PA, LD, QL, SP, ST or AC, providers must include supporting clinical documentation with the PA request. Documentation should show diagnosis, prior therapies tried (for ST), rationale for medical necessity, dosing and duration, and any lab or test results required by the PA criteria. For LD/SP products, documentation must also support use of the specialty or limited distributor.

    • PA requests should include: patient diagnosis, prior therapy history (relevant to ST), clinical notes, lab results, and proposed dosing.
    • For ST: document failure, intolerance, or contraindication to required first-line agents to support an exception.
    • QL documentation: justify medical need for quantities exceeding listed QL with clinical evidence.
    • LD/SP documentation: include ordering provider details and confirmation of appropriate specialty pharmacy or distributor.
    Step Therapy

    Step therapy and specialty program notes

    Step therapy is used selectively in this formulary. While many entries do not show explicit step sequences, select branded agents are flagged with ST and require trial of preferred agents first or documentation of a contraindication/intolerance. Providers may request exceptions with supporting clinical evidence.

    • KERENDIA (finerenone) is flagged with ST — ensure step edits are satisfied or document rationale for exception.
    • FOSRENOL, FERRIC CITRATE and some renal agents show ST in Requirements/Limits where noted.
    • Where ST is not specified, PA, QL, LD, and SP remain the primary management controls.

    Step therapy markers and affected products

    SummarySource evidence
    Markers such as AC, SP, LD (and related Requirement/Limit codes) indicate that additional authorization or specialty distribution steps may be required prior to coverage; the document does not provide explicit step-therapy sequences.
    Examples: ARIKAYCE shows Requirements/Limits = LD, PA, QL, SP; APRETUDE shows AC, LD, SP — entries use these markers to signal extra handling/authorization rather than explicit step pathways.
    SummarySource evidence
    Certain HCV agents and specialty antivirals require prior authorization and are often designated for specialty or limited distribution channels.
    Examples: LEDIPASVIR/SOFOSBUVIR (Requirements/Limits = PA, QL (28/28 days), SP); MAVYRET (Requirements/Limits = PA, QL (84/28 days), SP); APRETUDE lists AC, LD, SP.
    SummarySource evidence
    Many antineoplastic and other specialty oncology agents require prior authorization and may be distributed via limited distribution or specialty pharmacy channels.
    Examples: abiraterone (PA, QL, SP); ALECENSA (LD, PA, QL, SP); dasatinib (PA, QL, SP); REZLIDHIA (LD, PA, QL, SP) — entries list PA, LD, QL, and SP routinely for oncology agents.
    SummarySource evidence
    The extract contains no explicit step-therapy sequences (fail-first algorithms); utilization controls shown are limited to PA (prior authorization), QL (quantity limits), LD (limited distribution), and SP (specialty pharmacy).
    Examples: dasatinib entries show PA and QL; ARIKAYCE shows LD, PA, QL, SP — controls are present but step sequences are not defined.
    SummarySource evidence
    SP (specialty) designation appears on many specialty agents; providers must follow the plan's specialty/step program requirements when SP is indicated.
    Examples: multiple oncology and biologic agents (dasatinib, ALECENSA, abiraterone) list SP alongside PA/QL, indicating specialty pharmacy routing is required for these products.
    SummarySource evidence
    No explicit step-therapy sequences are provided in this segment; listings primarily show prior authorization (PA) and quantity limit (QL) flags for products.
    Examples: MOUNJARO entries show PA and QL; many oncology lines list PA and QL without specifying step therapy algorithms.
    ProductStep therapy statusSource evidence
    KERENDIA (finerenone)
    ST required
    KERENDIA entry lists Requirements/Limits = QL (30 tablets/30 days), ST
    SummarySource evidence
    LD (limited distribution) or SP (specialty) designations indicate that specialty dispensing pathways or restricted distribution channels may be prerequisites before coverage is approved for some products.
    Examples: REVCOVI lists LD, SP; ARIKAYCE lists LD, PA, QL, SP; ROZLYTREK entries show LD, PA, QL, SP — these flags denote required distribution channels.
    SummarySource evidence
    Some products in the formulary are flagged ST (step therapy); examples in the document include FOSRENOL and certain antidepressant specialty items such as FETZIMA and delayed‑release FLUOXETINE formulations.
    Evidence: FOSRENOL entries include ST in Requirements/Limits; FETZIMA and FLUOXETINE DR entries include ST alongside QL values.
    ProductStep therapy statusSource evidence
    Fetzima (levomilnacipran) and titration pack
    ST required
    FETZIMA entries show Requirements/Limits = QL (30 capsules/30 days), ST; titration pack entries also list ST.
    ProductStep therapy statusSource evidence
    Fanapt titration packs (iloperidone titration packs)
    ST required
    FANAPT TITRATION PACK entries list Requirements/Limits = QL (1 pack/180 days) and ST.
    SummarySource evidence
    SAVELLA and some other agents are marked 'ST' indicating step therapy is required prior to coverage for those products.
    Examples: the extract notes SAVELLA and lists other products with Requirements/Limits including ST (e.g., entries in chunks showing ST for certain analgesics and psychotropics).
    SummarySource evidence
    Step therapy (ST) applies to products flagged with 'ST' in the Requirements/Limits field; the document identifies several such agents but does not provide full step sequences within this extract.
    Examples: FOSRENOL lines include ST; antidepressant and psychotropic entries (FETZIMA, FLUOXETINE DR, FANAPT titration packs) are labeled ST per the formulary listing.

    Per-product quantity limits and examples

    Per-product quantity limits (overview)
    Per-product QL listingsMultiple products (ARIKAYCE, itraconazole, ISENTRESS, MAVYRET, etc.) have explicit QL values listed in the formulary lines; see each product's Requirements/Limits for the exact quantity and period.
    ISENTRESS HD (example)QL (60 tablets/30 days)
    LEDIPASVIR/SOFOSBUVIR (example)PA, QL (28 tablets/28 days), SP
    MAVYRET (example)PA, QL (84 tablets/28 days), SP
    ISENTRESS HD and related entries
    ISENTRESS HD (raltegravir 600 mg)QL (60 tablets/30 days)
    JULUCA (dolutegravir-rilpivirine)QL (30 tablets/30 days)
    KALETRA (lopinavir-ritonavir soln)QL (480 mls/30 days)
    Ledipasvir/sofosbuvir and related HCV agents
    LEDIPASVIR/SOFOSBUVIR (90-400 mg)PA, QL (28 tablets/28 days), SP
    SOVALDI (sofosbuvir)PA, QL (28 tablets/28 days), SP
    VOSEVI (sofosbuvir-velpatasvir-voxilaprevir)PA, QL (28 tablets/28 days), SP
    MAVYRET quantity limit examples
    MAVYRET (glecaprevir-pibrentasvir 100-40 mg)PA, QL (84 tablets/28 days), SP
    MAVYRET pellet packPA, QL (140 packets/28 days), SP
    Other HCV regimensMultiple products list PA, QL (per 28-day period), and SP as applicable
    Sofosbuvir-containing products
    SOFOSBUVIR/VELPATASVIR (400-100 mg)PA, QL (28 tablets/28 days), SP
    SOVALDI (sofosbuvir)PA, QL (28 tablets/28 days), SP
    VOSEVIPA, QL (28 tablets/28 days), SP
    Abiraterone quantity limits
    abiraterone acetate 250 mg (Zytiga)PA, QL (120 tablets/30 days), SP
    abiraterone acetate 500 mg (Zytiga)PA, QL (60 tablets/30 days), SP
    YONSA (micronized abiraterone)LD, PA, QL (120 tablets/30 days), SP
    Abiraterone 500 mg QL
    abiraterone acetate 500 mgPA, QL (60 tablets/30 days)
    abiraterone acetate 250 mgPA, QL (120 tablets/30 days)
    Zytiga entriesListed with SP designation
    ALECENSA and ALUNBRIG quantity limits
    ALECENSA (alectinib)LD, PA, QL (240 capsules/30 days), SP
    ALUNBRIG initiation pack (brigatinib)LD, PA, QL (30 tablets/180 days), SP
    ALUNBRIG regular packLD, PA, QL (120 tablets/30 days), SP
    ALUNBRIG initiation pack example
    ALUNBRIG initiation pack (30 tablets)LD, PA, QL (30 tablets/180 days)
    ALUNBRIG (30/90/120 tablet packs)Various QLs depending on pack and strength
    ALUNBRIG routingSP, LD indicated
    Dasatinib quantity limits by strength
    dasatinib (Sprycel) various strengthsPA, QL (30 or 90 tablets/30 days depending on strength), SP
    dasatinib 20 mgPA, QL (90 tablets/30 days)
    dasatinib higher strengthsPA, QL (30 tablets/30 days)
    KOSELUGO quantity limit examples
    KOSELUGO (selumetinib) 10 mg exampleLD, PA, QL (240 capsules/30 days) — example for 10 mg strength
    KOSELUGO 25 mgLD, PA, QL (120 capsules/30 days)
    KOSELUGO sprinkle formsHigher QLs listed (e.g., 420 capsules/30 days) depending on formulation
    LUMAKRAS quantity examples
    LUMAKRAS (sotorasib) 120 mgLD, PA, QL (240 tablets/30 days)
    LUMAKRAS 240 mgLD, PA, QL (120 tablets/30 days)
    LUMAKRAS 320 mgLD, PA, QL (90 tablets/30 days)
    Selected oncology QLs (capsules/packets)
    REZLIDHIA (olutasidenib)LD, PA, QL (60 capsules/30 days), SP
    ROMVIMZA (vimseltinib)PA, QL (8 capsules/28 days), SP
    ROZLYTREK (entrectinib) pelletLD, PA, QL (336 packets/28 days), SP
    VITRAKVI quantity limits (solution and capsules)
    VITRAKVI (oral solution)LD, PA, QL (300 mls/30 days), SP
    VITRAKVI (25 mg capsules)LD, PA, QL (180 capsules/30 days), SP
    VITRAKVI other strengthsSee per-strength QL entries
    VITRAKVI capsules QL
    VITRAKVI 25 mg capsulesLD, PA, QL (180 capsules/30 days)
    VITRAKVI oral solutionLD, PA, QL (300 mls/30 days)
    SP/LD designationSpecialty handling indicated
    XTANDI quantity limits
    XTANDI (enzalutamide) 40 mgLD, PA, QL (120 capsules/30 days), SP
    XTANDI 80 mgLD, PA, QL (60 tablets/30 days), SP
    XTANDI formulationsListed with LD/PA/QL and SP
    CLIMARA PRO and patch QLs
    CLIMARA PRO patchQL (4 patches/28 days)
    COMBIPATCHQL (8 patches/28 days)
    Other transdermal estradiol productsVarious QLs listed per product
    Estradiol gel quantity limits
    Estradiol gel (Estrogel)QL (1 pump/30 days)
    EleStrin / Divigel entriesVarious gel/packet QLs (e.g., 30 packets/30 days)
    Transdermal/gel QLsSpecific QLs vary by product, see Requirements/Limits
    Selected antidiabetic agent QLs
    FARXIGA (dapagliflozin)QL (30 tablets/30 days)
    MOUNJARO (tirzepatide)PA, QL (4 pens/180 days) generally; some strengths: QL (4 pens/28 days)
    OZEMPIC (semaglutide)PA, QL (1 pen/28 days) for some strengths; QL (3 pens/28 days) for other strengths
    MOUNJARO / OZEMPIC pen limits
    MOUNJAROPA, QL (4 pens/180 days); for some strengths: QL (4 pens/28 days)
    OZEMPICPA, QL (1 pen/28 days) for some strengths; QL (3 pens/28 days) for other strengths
    RYBELSUSPA, QL (30 tablets/180 days or 30 tablets/30 days depending on strength)
    Insulin QL across products
    Insulin formulations (multiple brands)QL (100 mls/30 days) for many insulin products (pens, cartridges, vials)
    FIASP / HUMALOG / NOVOLOG examplesRequirements/Limits = QL (100 mls/30 days)
    Basal insulins (e.g., glargine, degludec)Requirements/Limits = QL (100 mls/30 days)
    Multiple insulin products — 100 mls/30 days
    HUMALOG mixes and HUMULIN / NOVOLIN mixesQL (100 mls/30 days)
    NOVOLOG / NOVOLOG PENFILLQL (100 mls/30 days)
    TRESIBA (degludec)QL (100 mls/30 days)
    GALAFOLD quantity limit
    GALAFOLD (migalastat)LD, PA, QL (14 capsules/28 days), SP
    GENOTROPINPA, SP indicated
    IMCIVREE (setmelanotide)LD, PA, QL (10 vials/30 days), SP
    IMCIVREE quantity limit
    IMCIVREE (setmelanotide)LD, PA, QL (10 vials/30 days), SP
    Associated specialty routingLD and SP flags present — specialty handling required
    Documentation neededPA/LD/QL documentation expected at authorization
    KERENDIA quantity limit and step therapy
    KERENDIA (finerenone)QL (30 tablets/30 days); flagged ST (step therapy)
    KERENDIA tieringDrug Tier = 2
    Step therapy noteST flag indicates step therapy applies
    JYNARQUE quantity limits (pack-dependent)
    JYNARQUE (tolvaptan) therapy packLD, PA, QL (56 tablets/28 days) for therapy pack; QL (60 tablets/30 days) for other pack
    JYNARQUE alternative packQL (30 tablets/30 days) for 30 mg strength entry
    LD/PA/SP designationSpecialty routing indicated
    OPFOLDA quantity limit
    OPFOLDA (miglustat)LD, PA, QL (8 capsules/28 days), SP
    Rare disease specialty routingLD and SP indicated
    PA/QL enforced at claim adjudicationDocumentation required
    Selected specialized injectable QLs
    TRYNGOLZA (olezarsen)LD, PA, QL (1 injection device/28 days), SP
    TYMLOS (abaloparatide)LD, PA, QL (1 pen/30 days), SP
    VOXZOGO (vosoritide)LD, PA, QL (30 vials/30 days), SP
    Parathyroid/osteoporosis pen QLs
    TYMLOS (abaloparatide)LD, PA, QL (1 pen/30 days), SP
    Forteo (teriparatide)PA, QL (1 pen/28 days)
    YORVIPATHLD, PA, QL (2 pens/28 days)
    Propranolol oral solution quantity limits
    Propranolol oral solution 40 mg/5mlPA, QL (2400 mls/30 days)
    Propranolol oral solution 20 mg/5mlPA, QL (4800 mls/30 days)
    NIMODIPINE / NYMALIZE solution examplesLarge-ml QLs specified per product (e.g., 1260 mls/21 days)
    Large-volume oral solution QLs
    chlorothiazide suspensionPA, QL (1200 mls/30 days)
    furosemide oral solution 10 mg/mlLD, PA, QL (1800 mls/30 days)
    nimodipine oral solutionsExamples: QL (1260 mls/21 days); QL (2520 mls/21 days)
    REPATHA and lipid/PAH agent QLs
    REPATHA (evolocumab)QL (6 syringes/28 days)
    NEXLETOL / NEXLIZETPA, QL (30 tablets/30 days)
    UPTRAVI (selexipag)LD, PA, QL (60 tablets/30 days), SP
    Miscellaneous product QL examples (respiratory, biologics, CNS, ADHD, sodium oxybate)
    Respiratory / biologic / CNS / ADHD QLsExamples include ARNUITY ELLIPTA QL (30 blisters/30 days); FASENRA PEN QL (1 pen/28 days); NUCALA QL (1-3 syringes/pens depending on presentation); TRIKAFTA packets QL (56 packets/28 days); desvenlafaxine QL (120 tablets/30 days); escitalopram solution QL (600 mls/30 days); multiple ADHD and stimulant agents with QLs varying by formulation (30–180 days).
    sodium oxybate (XYREM/XYWAV/LUMRYZ)LD, PA, QL (540 mls/30 days)
    Aimovig (erenumab)PA, QL (1 injection device/28 days)

    Specialty, limited distribution, and channel routing

    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Abbreviations and Requirement/Limit code meanings

    Formulary grouping and scope

    Background: This formulary groups drugs by therapeutic class and indicates assigned Drug Tiers together with utilization management codes used during adjudication. Common flags include PA (prior authorization), QL (quantity limit, often shown with exact quantities and time intervals), LD (limited distribution), SP (specialty pharmacy), and occasionally AC for vaccine administrative coding. Providers should use the Requirements/Limits annotations on each drug line to determine whether prior authorization, documentation, specialty routing, or quantity restrictions apply.

    Biosimilar listings and associated requirements

    Note